IL6 and migraine disorder: They demonstrate that PAR2 activation and IL-6 signaling can prime a NO donor through different methods. Targeting IL-6 in people is currently being tested, but its efficacy in migraine has yet to be determined. This study, together with previous research, strongly suggests that PAR2 may be a promising therapeutic target for migraine.